{"classes":[{"title":"From baseline to Cycle 3 day 1 of study therapy"},{"title":"From baseline to time of progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Circulating MM cells isolated from peripheral blood","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"populationDescription":"All treated participants with available circulating MM cells. Circulating MM cells were not collected for any of the participants.","reportingStatus":"POSTED","timeFrame":"From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)","title":"Change From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells","type":"SECONDARY"}